Ophthalmology and Therapy, 2022 Ladder was a phase 2 trial that evaluated the Port Delivery System with ranibizumab (PDS) for neovascular age-related macular degeneration. Serum and aqueous humor samples were collected to characterize the pharmacokinetics (PK) of ranibizumab delivered ...
C. Wykoff +8 more
semanticscholar +1 more source
Ranibizumab in neovascular age-related macular degeneration
Clinical Interventions in Aging, 2006 Neovascular age-related macular degeneration (AMD) is a visually devastating condition resulting from choroidal neovascularization and secondary photoreceptor loss.
K. Eng, P. Kertes
semanticscholar +1 more source
Ranibizumab and bevacizumab for neovascular age-related macular degeneration.
New England Journal of Medicine, 2011 BACKGROUND Clinical trials have established the efficacy of ranibizumab for the treatment of neovascular age-related macular degeneration (AMD). In addition, bevacizumab is used off-label to treat AMD, despite the absence of similar supporting data ...
Daniel F. Martin +5 more
semanticscholar +1 more source
Ranibizumab for neovascular age-related macular degeneration.
New England Journal of Medicine, 2006 BACKGROUND Ranibizumab--a recombinant, humanized, monoclonal antibody Fab that neutralizes all active forms of vascular endothelial growth factor A--has been evaluated for the treatment of neovascular age-related macular degeneration.
P. Rosenfeld +6 more
semanticscholar +1 more source
JAMA ophthalmology, 2020 This randomized clinical trial (EVEREST II) compares intravitreal ranibizumab with or without verteporfin photodynamic therapy among Asian patients with polypoidal choroidal vasculopathy at 24 months.
T. Lim +12 more
semanticscholar +1 more source
Early CRT monitoring using time-domain optical coherence tomography does not add to visual acuity for predicting visual loss in patients with central retinal vein occlusion treated with intravitreal ranibizumab:A secondary analysis of trial data [PDF]
, 2017 Our primary purpose was to assess the clinical (predictive) validity of central retinal thickness (CRT) and best corrected visual acuity (BCVA) at 1 week and 1 month after starting treatment with ranibizumab for central retinal vein occlusion.
Bell, Katy J L +8 more
core +2 more sources
Cost-effectiveness of ranibizumab in treatment of diabetic macular oedema (DME) causing visual impairment : evidence from the RESTORE trial [PDF]
, 2012 Background/aims To evaluate the cost-effectiveness of ranibizumab as either monotherapy or combined with laser therapy, compared with laser monotherapy, in the treatment of diabetic macular oedema (DME) causing visual impairment from a UK healthcare ...
Annemans, Lieven +7 more
core +3 more sources
Clinical Ophthalmology, 2021 Faye Horner, Peck Lin Lip, Bashar R Mohammed, William Fusi-Rubiano, Eesha Gokhale, Bushra Mushtaq, Randhir Chavan Birmingham & Midland Eye Centre, Birmingham, UKCorrespondence: Randhir ChavanBirmingham & Midland Eye Centre, Sandwell & West ...
Horner F +6 more
doaj
PLoS ONE, 2020 PurposeTo evaluate the effectiveness, safety, and treatment patterns of ranibizumab 0.5 mg in prior ranibizumab-treated patients with neovascular age-related macular degeneration (nAMD) enrolled in the LUMINOUS™ study.Patients and methodsLUMINOUS, a 5 ...
Frank G Holz +6 more
doaj +1 more source
Comparison of Intravitreal Bevacizumab Upload Followed by a Dexamethasone Implant versus Dexamethasone Implant Monotherapy for Retinal Vein Occlusion with Macular Edema [PDF]
, 2012 Purpose: To compare the efficacy and safety of three intravitreal bevacizumab upload injections followed by a dexamethasone implant versus dexamethasone implant monotherapy in eyes with macular edema due to retinal vein occlusion.
Haritoglou, Christos +7 more
core +1 more source